Director at Inhibitor Therapeutics (INTI) receives 50K restricted shares

Rhea-AI Filing Summary

SEARS SAMUEL P JR reported acquisition or exercise transactions in this Form 4 filing.

Inhibitor Therapeutics, Inc. director Samuel P. Sears Jr. received a grant of 50,000 shares of restricted common stock on May 4, 2026 as compensation under the 2025 Equity Incentive Plan, subject to shareholder approval. After this award, he directly holds 1,229,543 common shares.

Insider Trade Summary

Net Buyer: 50,000 shares

Net Buy 1 txn

Insider SEARS SAMUEL P JR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	50,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,229,543 shares (Direct)

Footnotes (1)

1. F1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.

Key Figures

Restricted stock grant: 50000.0000 shares Grant price: 0.0000 per share Holdings after grant: 1229543.0000 shares +1 more

4 metrics

Restricted stock grant 50000.0000 shares Shares of common stock granted on 2026-05-04

Grant price 0.0000 per share Reported transaction price for the restricted stock award

Holdings after grant 1229543.0000 shares Total common shares directly held by Samuel P. Sears Jr. following the award

Transaction date 2026-05-04 Date of the reported stock award to the director

Key Terms

restricted common stock, 2025 Equity Incentive Plan, subject to shareholder approval

3 terms

restricted common stock financial

"Represents restricted common stock issued to the Reporting Person as compensation"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

2025 Equity Incentive Plan financial

"as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval"

subject to shareholder approval regulatory

"pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 12:15 PM Accepted by SEC EDGAR 08/04/2026 - 12:15 PM Learn about SEC filing dates

FAQ

What insider transaction did INTI report for Samuel P. Sears Jr.?

Samuel P. Sears Jr., a director of Inhibitor Therapeutics, received a grant of 50,000 shares of restricted common stock on May 4, 2026. The award was issued as compensation under the company’s 2025 Equity Incentive Plan, subject to shareholder approval.

How many INTI shares does Samuel P. Sears Jr. own after this grant?

After the reported grant, Samuel P. Sears Jr. directly holds 1,229,543 shares of Inhibitor Therapeutics common stock. This figure reflects his total direct ownership immediately following the 50,000-share restricted stock award disclosed in the Form 4 filing.

Was the INTI stock award to Samuel P. Sears Jr. made under a Rule 10b5-1 plan?

The transaction was not reported as being made pursuant to a Rule 10b5-1 trading plan. The filing’s specific Rule 10b5-1 checkbox was left unchecked, indicating the award was not executed under a pre-arranged trading arrangement.

What are the key terms of the INTI share grant to Samuel P. Sears Jr.?

Samuel P. Sears Jr. received 50,000 shares of restricted common stock, reported at a price of $0.0000 per share. The shares were granted as compensation under the 2025 Equity Incentive Plan and are subject to approval by Inhibitor Therapeutics shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEARS SAMUEL P JR

(Last) (First) (Middle)

C/O INHIBITOR THERAPEUTICS, INC.,

3014 WEST PALMIRA AVE SUITE 302

(Street)

TAMPA FLORIDA 33629

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		50,000(1)	A	$0	1,229,543	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.

	/s/ Samuel P. Sears	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)